Vericel (VCEL) Scheduled to Post Earnings on Wednesday

Vericel (NASDAQ:VCEL) will announce its earnings results before the market opens on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.11) per share for the quarter. Vericel has set its FY 2024 guidance at EPS.Parties that are interested in participating in the company’s conference call can do so using this link.

Vericel (NASDAQ:VCEL) last released its quarterly earnings results on Thursday, February 29th. The biotechnology company reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of $0.18 by $0.08. The business had revenue of $65.00 million for the quarter, compared to analysts’ expectations of $64.28 million. Vericel had a negative net margin of 1.61% and a negative return on equity of 1.55%. The company’s revenue was up 23.3% compared to the same quarter last year. During the same period last year, the business earned $0.12 EPS. On average, analysts expect Vericel to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Vericel Stock Down 1.7 %

NASDAQ VCEL opened at $45.87 on Wednesday. The firm’s fifty day simple moving average is $47.26 and its two-hundred day simple moving average is $41.09. Vericel has a 12-month low of $30.18 and a 12-month high of $53.05.

Wall Street Analysts Forecast Growth

VCEL has been the subject of several research analyst reports. TheStreet raised shares of Vericel from a “d+” rating to a “c-” rating in a research report on Monday, January 29th. Truist Financial reaffirmed a “buy” rating and set a $54.00 price target on shares of Vericel in a research report on Tuesday, March 26th. Finally, HC Wainwright increased their price objective on Vericel from $46.00 to $53.00 and gave the company a “buy” rating in a report on Friday, March 1st. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, Vericel presently has an average rating of “Moderate Buy” and an average price target of $46.40.

Insider Activity at Vericel

In other news, SVP Sean C. Flynn sold 8,115 shares of the stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $45.33, for a total transaction of $367,852.95. Following the transaction, the senior vice president now owns 167 shares in the company, valued at approximately $7,570.11. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, SVP Sean C. Flynn sold 8,115 shares of the business’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $45.33, for a total transaction of $367,852.95. Following the completion of the sale, the senior vice president now owns 167 shares of the company’s stock, valued at $7,570.11. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert L. Md Zerbe sold 3,278 shares of the firm’s stock in a transaction dated Wednesday, March 27th. The shares were sold at an average price of $51.57, for a total transaction of $169,046.46. Following the completion of the transaction, the director now directly owns 23,395 shares in the company, valued at $1,206,480.15. The disclosure for this sale can be found here. Insiders sold a total of 54,267 shares of company stock worth $2,450,996 in the last 90 days. Corporate insiders own 7.20% of the company’s stock.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.